カテゴリー： Market Monitor Global, 世界, 医療/バイオ

代謝疾患治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Metabolic Disease Therapeutics Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5762）

◆商品コード：MMG23JU5762
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：69
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Metabolic Disease Therapeutics Market 調査レポートは次の情報を含め、グローバルにおけるの代謝疾患治療薬市場規模と予測を収録しています。・世界の代謝疾患治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の代謝疾患治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の代謝疾患治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「グリコーゲン代謝疾患治療薬」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

代謝疾患治療薬のグローバル主要企業は、Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Beohrigher Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharmaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、代謝疾患治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の代謝疾患治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の代謝疾患治療薬市場：タイプ別市場シェア、2022年
・グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝疾患治療薬、その他

世界の代謝疾患治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の代謝疾患治療薬市場：用途別市場シェア、2022年
・病院薬局、小売薬局

世界の代謝疾患治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の代謝疾患治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における代謝疾患治療薬のグローバル売上、2018年-2023年
・主要企業における代謝疾患治療薬のグローバル売上シェア、2022年
・主要企業における代謝疾患治療薬のグローバル販売量、2018年-2023年
・主要企業における代謝疾患治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Beohrigher Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharma

*************************************************************

・調査・分析レポートの概要
代謝疾患治療薬市場の定義
市場セグメント
世界の代謝疾患治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の代謝疾患治療薬市場規模
世界の代謝疾患治療薬市場規模：2022年 VS 2029年
世界の代謝疾患治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの代謝疾患治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の代謝疾患治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝疾患治療薬、その他
代謝疾患治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局
代謝疾患治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別代謝疾患治療薬市場規模 2022年と2029年
地域別代謝疾患治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Beohrigher Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharma
...

Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
This report aims to provide a comprehensive presentation of the global market for Metabolic Disease Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disease Therapeutics. This report contains market size and forecasts of Metabolic Disease Therapeutics in global, including the following market information:
Global Metabolic Disease Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Metabolic Disease Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Glycogen Metabolism Disease Drug Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Metabolic Disease Therapeutics include Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Beohrigher Ingelheim, KOWA, Kythera, Fuji yakuhin and LG Life Science, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metabolic Disease Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metabolic Disease Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Metabolic Disease Therapeutics Market Segment Percentages, by Type, 2022 (%)
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Global Metabolic Disease Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Metabolic Disease Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Global Metabolic Disease Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Metabolic Disease Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metabolic Disease Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Metabolic Disease Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Beohrigher Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Metabolic Disease Therapeutics, market overview.
Chapter 2: Global Metabolic Disease Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Metabolic Disease Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Metabolic Disease Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Metabolic Disease Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metabolic Disease Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metabolic Disease Therapeutics Overall Market Size
2.1 Global Metabolic Disease Therapeutics Market Size: 2022 VS 2029
2.2 Global Metabolic Disease Therapeutics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Metabolic Disease Therapeutics Players in Global Market
3.2 Top Global Metabolic Disease Therapeutics Companies Ranked by Revenue
3.3 Global Metabolic Disease Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Metabolic Disease Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Metabolic Disease Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Metabolic Disease Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Metabolic Disease Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Metabolic Disease Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Metabolic Disease Therapeutics Market Size Markets, 2022 & 2029
4.1.2 Glycogen Metabolism Disease Drug
4.1.3 Lipid Metabolism Disease Drug
4.1.4 Amino Acid Metabolism Drug
4.1.5 Other
4.2 By Type – Global Metabolic Disease Therapeutics Revenue & Forecasts
4.2.1 By Type – Global Metabolic Disease Therapeutics Revenue, 2018-2023
4.2.2 By Type – Global Metabolic Disease Therapeutics Revenue, 2024-2029
4.2.3 By Type – Global Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Metabolic Disease Therapeutics Market Size, 2022 & 2029
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.2 By Application – Global Metabolic Disease Therapeutics Revenue & Forecasts
5.2.1 By Application – Global Metabolic Disease Therapeutics Revenue, 2018-2023
5.2.2 By Application – Global Metabolic Disease Therapeutics Revenue, 2024-2029
5.2.3 By Application – Global Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Metabolic Disease Therapeutics Market Size, 2022 & 2029
6.2 By Region – Global Metabolic Disease Therapeutics Revenue & Forecasts
6.2.1 By Region – Global Metabolic Disease Therapeutics Revenue, 2018-2023
6.2.2 By Region – Global Metabolic Disease Therapeutics Revenue, 2024-2029
6.2.3 By Region – Global Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Metabolic Disease Therapeutics Revenue, 2018-2029
6.3.2 US Metabolic Disease Therapeutics Market Size, 2018-2029
6.3.3 Canada Metabolic Disease Therapeutics Market Size, 2018-2029
6.3.4 Mexico Metabolic Disease Therapeutics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Metabolic Disease Therapeutics Revenue, 2018-2029
6.4.2 Germany Metabolic Disease Therapeutics Market Size, 2018-2029
6.4.3 France Metabolic Disease Therapeutics Market Size, 2018-2029
6.4.4 U.K. Metabolic Disease Therapeutics Market Size, 2018-2029
6.4.5 Italy Metabolic Disease Therapeutics Market Size, 2018-2029
6.4.6 Russia Metabolic Disease Therapeutics Market Size, 2018-2029
6.4.7 Nordic Countries Metabolic Disease Therapeutics Market Size, 2018-2029
6.4.8 Benelux Metabolic Disease Therapeutics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Metabolic Disease Therapeutics Revenue, 2018-2029
6.5.2 China Metabolic Disease Therapeutics Market Size, 2018-2029
6.5.3 Japan Metabolic Disease Therapeutics Market Size, 2018-2029
6.5.4 South Korea Metabolic Disease Therapeutics Market Size, 2018-2029
6.5.5 Southeast Asia Metabolic Disease Therapeutics Market Size, 2018-2029
6.5.6 India Metabolic Disease Therapeutics Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Metabolic Disease Therapeutics Revenue, 2018-2029
6.6.2 Brazil Metabolic Disease Therapeutics Market Size, 2018-2029
6.6.3 Argentina Metabolic Disease Therapeutics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Metabolic Disease Therapeutics Revenue, 2018-2029
6.7.2 Turkey Metabolic Disease Therapeutics Market Size, 2018-2029
6.7.3 Israel Metabolic Disease Therapeutics Market Size, 2018-2029
6.7.4 Saudi Arabia Metabolic Disease Therapeutics Market Size, 2018-2029
6.7.5 UAE Metabolic Disease Therapeutics Market Size, 2018-2029
7 Metabolic Disease Therapeutics Companies Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Metabolic Disease Therapeutics Major Product Offerings
7.1.4 Merck Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Metabolic Disease Therapeutics Major Product Offerings
7.2.4 Novartis Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Company Summary
7.3.2 Takeda Pharmaceutical Business Overview
7.3.3 Takeda Pharmaceutical Metabolic Disease Therapeutics Major Product Offerings
7.3.4 Takeda Pharmaceutical Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Takeda Pharmaceutical Key News & Latest Developments
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Summary
7.4.2 Astra Zeneca Business Overview
7.4.3 Astra Zeneca Metabolic Disease Therapeutics Major Product Offerings
7.4.4 Astra Zeneca Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Astra Zeneca Key News & Latest Developments
7.5 Beohrigher Ingelheim
7.5.1 Beohrigher Ingelheim Company Summary
7.5.2 Beohrigher Ingelheim Business Overview
7.5.3 Beohrigher Ingelheim Metabolic Disease Therapeutics Major Product Offerings
7.5.4 Beohrigher Ingelheim Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Beohrigher Ingelheim Key News & Latest Developments
7.6 KOWA
7.6.1 KOWA Company Summary
7.6.2 KOWA Business Overview
7.6.3 KOWA Metabolic Disease Therapeutics Major Product Offerings
7.6.4 KOWA Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.6.5 KOWA Key News & Latest Developments
7.7 Kythera
7.7.1 Kythera Company Summary
7.7.2 Kythera Business Overview
7.7.3 Kythera Metabolic Disease Therapeutics Major Product Offerings
7.7.4 Kythera Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.7.5 Kythera Key News & Latest Developments
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Company Summary
7.8.2 Fuji yakuhin Business Overview
7.8.3 Fuji yakuhin Metabolic Disease Therapeutics Major Product Offerings
7.8.4 Fuji yakuhin Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.8.5 Fuji yakuhin Key News & Latest Developments
7.9 LG Life Science
7.9.1 LG Life Science Company Summary
7.9.2 LG Life Science Business Overview
7.9.3 LG Life Science Metabolic Disease Therapeutics Major Product Offerings
7.9.4 LG Life Science Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.9.5 LG Life Science Key News & Latest Developments
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Company Summary
7.10.2 Metsubishi Tanabe Pharma Business Overview
7.10.3 Metsubishi Tanabe Pharma Metabolic Disease Therapeutics Major Product Offerings
7.10.4 Metsubishi Tanabe Pharma Metabolic Disease Therapeutics Revenue in Global Market (2018-2023)
7.10.5 Metsubishi Tanabe Pharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Metabolic Disease Therapeutics Market Opportunities & Trends in Global Market
Table 2. Metabolic Disease Therapeutics Market Drivers in Global Market
Table 3. Metabolic Disease Therapeutics Market Restraints in Global Market
Table 4. Key Players of Metabolic Disease Therapeutics in Global Market
Table 5. Top Metabolic Disease Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Metabolic Disease Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Metabolic Disease Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Metabolic Disease Therapeutics Product Type
Table 9. List of Global Tier 1 Metabolic Disease Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Metabolic Disease Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Metabolic Disease Therapeutics Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Metabolic Disease Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Metabolic Disease Therapeutics Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Metabolic Disease Therapeutics Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Metabolic Disease Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Metabolic Disease Therapeutics Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Metabolic Disease Therapeutics Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Metabolic Disease Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Metabolic Disease Therapeutics Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Metabolic Disease Therapeutics Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Metabolic Disease Therapeutics Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Metabolic Disease Therapeutics Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Metabolic Disease Therapeutics Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Metabolic Disease Therapeutics Revenue, (US$, Mn), 2024-2029
Table 30. Merck Company Summary
Table 31. Merck Metabolic Disease Therapeutics Product Offerings
Table 32. Merck Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. Merck Key News & Latest Developments
Table 34. Novartis Company Summary
Table 35. Novartis Metabolic Disease Therapeutics Product Offerings
Table 36. Novartis Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Novartis Key News & Latest Developments
Table 38. Takeda Pharmaceutical Company Summary
Table 39. Takeda Pharmaceutical Metabolic Disease Therapeutics Product Offerings
Table 40. Takeda Pharmaceutical Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. Takeda Pharmaceutical Key News & Latest Developments
Table 42. Astra Zeneca Company Summary
Table 43. Astra Zeneca Metabolic Disease Therapeutics Product Offerings
Table 44. Astra Zeneca Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Astra Zeneca Key News & Latest Developments
Table 46. Beohrigher Ingelheim Company Summary
Table 47. Beohrigher Ingelheim Metabolic Disease Therapeutics Product Offerings
Table 48. Beohrigher Ingelheim Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. Beohrigher Ingelheim Key News & Latest Developments
Table 50. KOWA Company Summary
Table 51. KOWA Metabolic Disease Therapeutics Product Offerings
Table 52. KOWA Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. KOWA Key News & Latest Developments
Table 54. Kythera Company Summary
Table 55. Kythera Metabolic Disease Therapeutics Product Offerings
Table 56. Kythera Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 57. Kythera Key News & Latest Developments
Table 58. Fuji yakuhin Company Summary
Table 59. Fuji yakuhin Metabolic Disease Therapeutics Product Offerings
Table 60. Fuji yakuhin Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 61. Fuji yakuhin Key News & Latest Developments
Table 62. LG Life Science Company Summary
Table 63. LG Life Science Metabolic Disease Therapeutics Product Offerings
Table 64. LG Life Science Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 65. LG Life Science Key News & Latest Developments
Table 66. Metsubishi Tanabe Pharma Company Summary
Table 67. Metsubishi Tanabe Pharma Metabolic Disease Therapeutics Product Offerings
Table 68. Metsubishi Tanabe Pharma Metabolic Disease Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 69. Metsubishi Tanabe Pharma Key News & Latest Developments
List of Figures
Figure 1. Metabolic Disease Therapeutics Segment by Type in 2022
Figure 2. Metabolic Disease Therapeutics Segment by Application in 2022
Figure 3. Global Metabolic Disease Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Metabolic Disease Therapeutics Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Metabolic Disease Therapeutics Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Metabolic Disease Therapeutics Revenue in 2022
Figure 8. By Type - Global Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 9. By Application - Global Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 10. By Type - Global Metabolic Disease Therapeutics Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 12. By Application - Global Metabolic Disease Therapeutics Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 14. By Region - Global Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 15. By Country - North America Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 16. US Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 20. Germany Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 21. France Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 28. China Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 32. India Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 34. Brazil Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Metabolic Disease Therapeutics Revenue Market Share, 2018-2029
Figure 37. Turkey Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Metabolic Disease Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 41. Merck Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Novartis Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Takeda Pharmaceutical Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Astra Zeneca Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Beohrigher Ingelheim Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. KOWA Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Kythera Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Fuji yakuhin Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. LG Life Science Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Metsubishi Tanabe Pharma Metabolic Disease Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 代謝疾患治療薬の世界市場見通し2023年-2029年(Metabolic Disease Therapeutics Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

代謝疾患治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp